Exact Mass: 688.3951

Exact Mass Matches: 688.3951

Found 226 metabolites which its exact mass value is equals to given mass value 688.3951, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

   

PA(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))

[(2R)-2,3-bis[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyloxy]propoxy]phosphonic acid

C39H61O8P (688.4104)


PA(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of stearidonic acid at the C-1 position and one chain of stearidonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

12-O-Retinoylphorbol-13-acetate

13-(acetyloxy)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0^{2,6}.0^{11,13}]pentadeca-3,8-dien-14-yl 3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoate

C42H56O8 (688.3975)


   

PA(12:0/PGE2)

PA(12:0/PGE2)

C35H61O11P (688.3951)


PA(12:0/PGE2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/PGE2), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGE2/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}propoxy]phosphonic acid

C35H61O11P (688.3951)


PA(PGE2/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE2/12:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/PGD2)

[(2R)-3-(dodecanoyloxy)-2-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}propoxy]phosphonic acid

C35H61O11P (688.3951)


PA(12:0/PGD2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/PGD2), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGD2/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}propoxy]phosphonic acid

C35H61O11P (688.3951)


PA(PGD2/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD2/12:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

[(2R)-3-(dodecanoyloxy)-2-{[(5S,6S,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O11P (688.3951)


PA(12:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O11P (688.3951)


PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/12:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(13:0/20:3(8Z,11Z,14Z)-2OH(5,6))

[(2R)-2-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-3-(tridecanoyloxy)propoxy]phosphonic acid

C36H65O10P (688.4315)


PA(13:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/13:0)

[(2R)-3-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-2-(tridecanoyloxy)propoxy]phosphonic acid

C36H65O10P (688.4315)


PA(20:3(8Z,11Z,14Z)-2OH(5,6)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/13:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/5-iso PGF2VI)

[(2R)-2-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H61O11P (688.3951)


PA(14:1(9Z)/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/5-iso PGF2VI), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(5-iso PGF2VI/14:1(9Z))

[(2R)-3-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H61O11P (688.3951)


PA(5-iso PGF2VI/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(5-iso PGF2VI/14:1(9Z)), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/20:3(8Z,11Z,14Z)-2OH(5,6))

[(2R)-2-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-3-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H65O10P (688.4315)


PA(a-13:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/a-13:0)

[(2R)-3-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-2-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H65O10P (688.4315)


PA(20:3(8Z,11Z,14Z)-2OH(5,6)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/a-13:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/PGE2)

[(2R)-2-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O11P (688.3951)


PA(i-12:0/PGE2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/PGE2), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGE2/i-12:0)

[(2R)-3-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O11P (688.3951)


PA(PGE2/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE2/i-12:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/PGD2)

[(2R)-2-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O11P (688.3951)


PA(i-12:0/PGD2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/PGD2), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGD2/i-12:0)

[(2R)-3-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O11P (688.3951)


PA(PGD2/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD2/i-12:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

[(2R)-3-[(10-methylundecanoyl)oxy]-2-{[(5S,6S,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O11P (688.3951)


PA(i-12:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-12:0)

[(2R)-2-[(10-methylundecanoyl)oxy]-3-{[(5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O11P (688.3951)


PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-12:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/20:3(8Z,11Z,14Z)-2OH(5,6))

[(2R)-2-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-3-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H65O10P (688.4315)


PA(i-13:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-13:0)

[(2R)-3-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-2-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H65O10P (688.4315)


PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-13:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Incarvillateine D

Incarvillateine D

C41H56N2O7 (688.4087)


   

Daedaleaside D

Daedaleaside D

C39H60O10 (688.4186)


   

Methylcimicifugoside

Methylcimicifugoside

C38H56O11 (688.3822)


   

Fumonisin Py4

Fumonisin Py4

C34H56O14 (688.367)


CONFIDENCE isolated standard

   

reveromycin D 4-methyl ester

reveromycin D 4-methyl ester

C38H56O11 (688.3822)


   

4-O-methylbutin-7-O-[(6->1)-3,11-dimethyl-7-hydroxymethylenedodecanyl]-beta-D-glucopyranoside

4-O-methylbutin-7-O-[(6->1)-3,11-dimethyl-7-hydroxymethylenedodecanyl]-beta-D-glucopyranoside

C37H52O12 (688.3459)


   

Xyloccensin F

Xyloccensin F

C37H52O12 (688.3459)


   

datiscoside H

datiscoside H

C38H56O11 (688.3822)


   

bacchalejin 2

bacchalejin 2

C43H60O7 (688.4339)


   
   

ecdysterone 22,25-di-O-benzoate

ecdysterone 22,25-di-O-benzoate

C41H52O9 (688.3611)


   

Sarmentogenin-3-pimeloylargininester

Sarmentogenin-3-pimeloylargininester

C36H56N4O9 (688.4047)


   

methyl (2S)-2-[(2R,3E,12bS)-3-ethylidene-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-[(2S,3R)-3-ethyl-2-[(1R)-1-(hydroxymethyl)-2-methoxy-2-oxo-ethyl]-1,2,3,4-tetrahydroindolo[2,3-a]quinolizin-5-ium-7-yl]propanoate|moandaensine

methyl (2S)-2-[(2R,3E,12bS)-3-ethylidene-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-[(2S,3R)-3-ethyl-2-[(1R)-1-(hydroxymethyl)-2-methoxy-2-oxo-ethyl]-1,2,3,4-tetrahydroindolo[2,3-a]quinolizin-5-ium-7-yl]propanoate|moandaensine

C42H48N4O5 (688.3625)


   

reveromycin E

reveromycin E

C38H56O11 (688.3822)


   

2-O-acetyl-3-O-(4-O-acetyl)-alpha-L-arabinopyranosylmaslinic acid

2-O-acetyl-3-O-(4-O-acetyl)-alpha-L-arabinopyranosylmaslinic acid

C39H60O10 (688.4186)


   

2-{[5,7-dihydroxy-2-methyl-2-(4-methyl-3-pentenyl)-8-butanoyl-6-chromenyl]-methyl}-3,5-dihydroxy-4-methyl-4-(3,7-dimethyl-2,6-octadienyl)-6-butanoyl-2,5-cyclohexadien-1-one

2-{[5,7-dihydroxy-2-methyl-2-(4-methyl-3-pentenyl)-8-butanoyl-6-chromenyl]-methyl}-3,5-dihydroxy-4-methyl-4-(3,7-dimethyl-2,6-octadienyl)-6-butanoyl-2,5-cyclohexadien-1-one

C42H56O8 (688.3975)


   

cucurbitacin F 16-O-(2?-O-acetyl-4?,6?-dideoxy-alpha-gluco-hex-3?-ulopyranoside)|datiscoside K

cucurbitacin F 16-O-(2?-O-acetyl-4?,6?-dideoxy-alpha-gluco-hex-3?-ulopyranoside)|datiscoside K

C38H56O11 (688.3822)


   

cimigenol-3-O-[2?-O-(E)-2-butenoyl]-alpha?L-arabinopyranoside

cimigenol-3-O-[2?-O-(E)-2-butenoyl]-alpha?L-arabinopyranoside

C39H60O10 (688.4186)


   

satosporin A

satosporin A

C34H56O14 (688.367)


   

hypercohin C

hypercohin C

C43H60O7 (688.4339)


   

2-O-acetyl-3-O-(3-O-acetyl)-alpha-L-arabinopyranosylmaslinic acid

2-O-acetyl-3-O-(3-O-acetyl)-alpha-L-arabinopyranosylmaslinic acid

C39H60O10 (688.4186)


   

6alpha-acetoxy-23alpha-ethoxy-16beta,23(R)-epoxy-24,25,26,27-tetranor-9,19-cyclolanosta-3-O-[beta-D-(4-trans-2-butenoyl)xylopyranoside]|tomentoside III

6alpha-acetoxy-23alpha-ethoxy-16beta,23(R)-epoxy-24,25,26,27-tetranor-9,19-cyclolanosta-3-O-[beta-D-(4-trans-2-butenoyl)xylopyranoside]|tomentoside III

C39H60O10 (688.4186)


   
   
   

reveromycin G

reveromycin G

C38H56O11 (688.3822)


   
   

Pleiokomenine B

Pleiokomenine B

C43H52N4O4 (688.3988)


   

PG(12:0/18:3(6Z,9Z,12Z))

1-dodecanoyl-2-(6Z,9Z,12Z-octadecatrienoyl)-glycero-3-phospho-(1-sn-glycerol)

C36H65O10P (688.4315)


   

PG(12:0/18:3(9Z,12Z,15Z))

1-dodecanoyl-2-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phospho-(1-sn-glycerol)

C36H65O10P (688.4315)


   

PG(18:3(6Z,9Z,12Z)/12:0)

1-(6Z,9Z,12Z-octadecatrienoyl)-2-dodecanoyl-glycero-3-phospho-(1-sn-glycerol)

C36H65O10P (688.4315)


   

PG(18:3(9Z,12Z,15Z)/12:0)

1-(9Z,12Z,15Z-octadecatrienoyl)-2-dodecanoyl-glycero-3-phospho-(1-sn-glycerol)

C36H65O10P (688.4315)


   

PA(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))

1,2-di-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-sn-glycero-3-phosphate

C39H61O8P (688.4104)


   

PG 30:3

1-(9Z,12Z,15Z-octadecatrienoyl)-2-dodecanoyl-glycero-3-phospho-(1-sn-glycerol)

C36H65O10P (688.4315)


   

PA 36:8

1,2-di-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-sn-glycero-3-phosphate

C39H61O8P (688.4104)


   
   

Uremic Pentapeptide (U5-Peptide)

Uremic Pentapeptide (U5-Peptide)

C32H48N8O9 (688.3544)


   
   

Vionactane

Vionactane

C25H46N13O10+3 (688.349)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D000995 - Antitubercular Agents D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors

   

(R)-1-(threo-4-Hydroxy-L-3,6-diaminohexanoic acid)-6-[L-2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)glycine]viomycin

(R)-1-(threo-4-Hydroxy-L-3,6-diaminohexanoic acid)-6-[L-2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)glycine]viomycin

C25H46N13O10+3 (688.349)


   

Phorbol-12-retinoate-13-acetate

Phorbol-12-retinoate-13-acetate

C42H56O8 (688.3975)


D009676 - Noxae > D002273 - Carcinogens > D010703 - Phorbol Esters

   

PA(i-12:0/PGE2)

PA(i-12:0/PGE2)

C35H61O11P (688.3951)


   

PA(PGE2/i-12:0)

PA(PGE2/i-12:0)

C35H61O11P (688.3951)


   

PA(i-12:0/PGD2)

PA(i-12:0/PGD2)

C35H61O11P (688.3951)


   

PA(PGD2/i-12:0)

PA(PGD2/i-12:0)

C35H61O11P (688.3951)


   
   
   
   
   

PA(14:1(9Z)/5-iso PGF2VI)

PA(14:1(9Z)/5-iso PGF2VI)

C35H61O11P (688.3951)


   

PA(5-iso PGF2VI/14:1(9Z))

PA(5-iso PGF2VI/14:1(9Z))

C35H61O11P (688.3951)


   

PA(13:0/20:3(8Z,11Z,14Z)-2OH(5,6))

PA(13:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C36H65O10P (688.4315)


   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/13:0)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/13:0)

C36H65O10P (688.4315)


   

PA(a-13:0/20:3(8Z,11Z,14Z)-2OH(5,6))

PA(a-13:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C36H65O10P (688.4315)


   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/a-13:0)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/a-13:0)

C36H65O10P (688.4315)


   

PA(i-13:0/20:3(8Z,11Z,14Z)-2OH(5,6))

PA(i-13:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C36H65O10P (688.4315)


   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-13:0)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-13:0)

C36H65O10P (688.4315)


   

PA(12:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

PA(12:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C35H61O11P (688.3951)


   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/12:0)

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/12:0)

C35H61O11P (688.3951)


   

PA(i-12:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

PA(i-12:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C35H61O11P (688.3951)


   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-12:0)

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-12:0)

C35H61O11P (688.3951)


   

Veraguamide C

Veraguamide C

C37H60N4O8 (688.4411)


A natural product found in Symploca hydnoides and Oscillatoria margaritifera PAC-17-FEB-10-2.

   

Viomycin(3+)

Viomycin(3+)

C25H46N13O10+3 (688.349)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D000995 - Antitubercular Agents D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors

   

Trichodepsipeptide A

Trichodepsipeptide A

C36H56N4O9 (688.4047)


A natural product found in Trichothecium speciesMSX 51320.

   

N-[[(3S,9R,10S)-16-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-2-phenylacetamide

N-[[(3S,9R,10S)-16-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-2-phenylacetamide

C38H48N4O8 (688.3472)


   

(9Z)-17-hydroxyoctadec-9-enoate 17-O-diacetylsophoroside 1,4-lactone

(9Z)-17-hydroxyoctadec-9-enoate 17-O-diacetylsophoroside 1,4-lactone

C34H56O14 (688.367)


   

(1R,9R,16R,21S)-6-[[(16R,21S)-18-methoxycarbonyl-2-methyl-2,12-diazahexacyclo[14.2.2.19,12.01,9.03,8.016,21]henicosa-3(8),4,6-trien-6-yl]methyl]-2,12-diazahexacyclo[14.2.2.19,12.01,9.03,8.016,21]henicosa-3(8),4,6-triene-18-carboxylic acid

(1R,9R,16R,21S)-6-[[(16R,21S)-18-methoxycarbonyl-2-methyl-2,12-diazahexacyclo[14.2.2.19,12.01,9.03,8.016,21]henicosa-3(8),4,6-trien-6-yl]methyl]-2,12-diazahexacyclo[14.2.2.19,12.01,9.03,8.016,21]henicosa-3(8),4,6-triene-18-carboxylic acid

C43H52N4O4 (688.3988)


   

Smgdg O-18:5_7:0

Smgdg O-18:5_7:0

C34H56O12S (688.3492)


   

Smgdg O-22:5_3:0

Smgdg O-22:5_3:0

C34H56O12S (688.3492)


   

Smgdg O-20:5_5:0

Smgdg O-20:5_5:0

C34H56O12S (688.3492)


   

Dgdg O-16:4_3:0

Dgdg O-16:4_3:0

C34H56O14 (688.367)


   

PEtOH 16:3_18:5

PEtOH 16:3_18:5

C39H61O8P (688.4104)


   

PEtOH 16:4_18:4

PEtOH 16:4_18:4

C39H61O8P (688.4104)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C36H65O10P (688.4315)


   

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C36H65O10P (688.4315)


   

[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C36H65O10P (688.4315)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-tetradecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-tetradecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C36H65O10P (688.4315)


   

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C36H65O10P (688.4315)


   

[1-[(2-dodecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[1-[(2-dodecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C36H65O10P (688.4315)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C36H65O10P (688.4315)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C36H65O10P (688.4315)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C36H65O10P (688.4315)


   

[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-phosphonooxypropyl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-phosphonooxypropyl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C39H61O8P (688.4104)


   

[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C36H65O10P (688.4315)


   

[2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropyl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropyl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C39H61O8P (688.4104)


   

[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C39H61O8P (688.4104)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C36H65O10P (688.4315)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C36H65O10P (688.4315)


   

[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C39H61O8P (688.4104)


   

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate

C36H65O10P (688.4315)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C36H65O10P (688.4315)


   

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C39H61O8P (688.4104)


   

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-dodecanoyloxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-dodecanoyloxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C36H65O10P (688.4315)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C36H65O10P (688.4315)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C36H65O10P (688.4315)


   

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C39H61O8P (688.4104)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

C36H65O10P (688.4315)


   

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoate

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoate

C39H61O8P (688.4104)


   

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C39H61O8P (688.4104)


   

[1-[(7E,9E)-tetradeca-7,9-dienoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-[(7E,9E)-tetradeca-7,9-dienoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C39H60O10 (688.4186)


   

[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate

[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate

C36H65O10P (688.4315)


   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

C39H61O8P (688.4104)


   

[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C39H61O8P (688.4104)


   

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-dodecanoyloxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-dodecanoyloxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C36H65O10P (688.4315)


   

[(2R)-1-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2R)-1-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C39H61O8P (688.4104)


   

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C39H61O8P (688.4104)


   

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate

C36H65O10P (688.4315)


   

[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

C36H65O10P (688.4315)


   

[1-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C39H60O10 (688.4186)


   

Viomycin(3+)

Viomycin(3+)

C25H46N13O10 (688.349)


Viomycin protonated to pH 7.3

   

1-dodecanoyl-2-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phospho-(1-sn-glycerol)

1-dodecanoyl-2-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phospho-(1-sn-glycerol)

C36H65O10P (688.4315)


   

oleandomycin(1+)

oleandomycin(1+)

C35H62NO12 (688.4272)


The conjugate acid of oleandomycin arising from protonation of the tertiary amino group; major species at pH 7.3.

   

MGDG O-30:8;O

MGDG O-30:8;O

C39H60O10 (688.4186)


   
   
   
   
   
   
   
   
   

PA 20:0/13:3;O2

PA 20:0/13:3;O2

C36H65O10P (688.4315)


   

PA 20:1/12:3;O3

PA 20:1/12:3;O3

C35H61O11P (688.3951)


   

PA 20:2/12:2;O3

PA 20:2/12:2;O3

C35H61O11P (688.3951)


   

PA 22:6/13:3;O

PA 22:6/13:3;O

C38H57O9P (688.374)


   
   
   
   
   
   
   
   

PG P-16:0/13:4;O2

PG P-16:0/13:4;O2

C35H61O11P (688.3951)


   

PG P-16:1/13:3;O2

PG P-16:1/13:3;O2

C35H61O11P (688.3951)


   

PG P-18:0/12:3;O

PG P-18:0/12:3;O

C36H65O10P (688.4315)


   

PG P-20:0/9:4;O2

PG P-20:0/9:4;O2

C35H61O11P (688.3951)


   
   
   
   
   
   
   
   
   
   
   
   
   

PEth 33:9;O

PEth 33:9;O

C38H57O9P (688.374)


   
   
   
   

ST 28:1;O8;GlcA

ST 28:1;O8;GlcA

C34H56O14 (688.367)


   

ST 29:0;O7;GlcA

ST 29:0;O7;GlcA

C35H60O13 (688.4034)


   

ST 29:1;O8;Hex

ST 29:1;O8;Hex

C35H60O13 (688.4034)


   

3-(1-{[3,5-dihydroxy-6-(hydroxymethyl)-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}ethyl)-4,6,7,10,12-pentamethyl-dodecahydro-3h-naphtho[1,2-c]oxocine-1,8-dione

3-(1-{[3,5-dihydroxy-6-(hydroxymethyl)-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}ethyl)-4,6,7,10,12-pentamethyl-dodecahydro-3h-naphtho[1,2-c]oxocine-1,8-dione

C34H56O14 (688.367)


   

(2e,4s,5s,6e,8e)-10-[(2r,3s,6s,8s,9r)-8-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-[(4-methoxy-4-oxobutanoyl)oxy]-3-methyl-9-pentyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

(2e,4s,5s,6e,8e)-10-[(2r,3s,6s,8s,9r)-8-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-[(4-methoxy-4-oxobutanoyl)oxy]-3-methyl-9-pentyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

C38H56O11 (688.3822)


   

1,3-bis({2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl}) 2-(4-hydroxy-3-methoxyphenyl)-4-(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

1,3-bis({2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl}) 2-(4-hydroxy-3-methoxyphenyl)-4-(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

C41H56N2O7 (688.4087)


   

(2s,5s,8s,11r,17r,18s)-12,15-dihydroxy-2,5,8-triisopropyl-11-[(4-methoxyphenyl)methyl]-4,10,18-trimethyl-17-propyl-1,7-dioxa-4,10,13,16-tetraazacyclononadeca-12,15-diene-3,6,9,19-tetrone

(2s,5s,8s,11r,17r,18s)-12,15-dihydroxy-2,5,8-triisopropyl-11-[(4-methoxyphenyl)methyl]-4,10,18-trimethyl-17-propyl-1,7-dioxa-4,10,13,16-tetraazacyclononadeca-12,15-diene-3,6,9,19-tetrone

C36H56N4O9 (688.4047)


   

(2r,3s,6s)-2-{[(1r,2r,3as,3bs,7s,8s,9ar,9br,11ar)-1-[(2r,4e)-2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl]-7,8-dihydroxy-3a,6,6,9b,11a-pentamethyl-10-oxo-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-2-yl]oxy}-6-methyl-5-oxooxan-3-yl acetate

(2r,3s,6s)-2-{[(1r,2r,3as,3bs,7s,8s,9ar,9br,11ar)-1-[(2r,4e)-2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl]-7,8-dihydroxy-3a,6,6,9b,11a-pentamethyl-10-oxo-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-2-yl]oxy}-6-methyl-5-oxooxan-3-yl acetate

C38H56O11 (688.3822)


   

methyl (2r)-2-[(2s,3r)-7-[(2s)-2-[(2r,3e,12bs)-3-ethylidene-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-2-yl]-3-methoxy-3-oxopropyl]-3-ethyl-1h,2h,3h,4h-indolo[2,3-a]quinolizin-2-yl]-3-hydroxypropanoate

methyl (2r)-2-[(2s,3r)-7-[(2s)-2-[(2r,3e,12bs)-3-ethylidene-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-2-yl]-3-methoxy-3-oxopropyl]-3-ethyl-1h,2h,3h,4h-indolo[2,3-a]quinolizin-2-yl]-3-hydroxypropanoate

C42H48N4O5 (688.3625)


   

1,2,6,6,10,19,22-heptamethyl-16-oxo-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-21-oxahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁸,²³]pentacos-14-en-8-yl acetate

1,2,6,6,10,19,22-heptamethyl-16-oxo-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-21-oxahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁸,²³]pentacos-14-en-8-yl acetate

C39H60O10 (688.4186)


   

1,3-bis[(4r,4as,6r,7s,7ar)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl] (1r,2r,3r,4s)-2-(4-hydroxy-3-methoxyphenyl)-4-(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

1,3-bis[(4r,4as,6r,7s,7ar)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl] (1r,2r,3r,4s)-2-(4-hydroxy-3-methoxyphenyl)-4-(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

C41H56N2O7 (688.4087)


   

(2e,4s,5s,6e,8e)-10-[(2r,5s,7r,8s)-2-[(1s,2e,4e)-5-carboxy-1-[(3-carboxypropanoyl)oxy]-4-methylpenta-2,4-dien-1-yl]-2-hexyl-8-methyl-1,6-dioxaspiro[4.5]decan-7-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

(2e,4s,5s,6e,8e)-10-[(2r,5s,7r,8s)-2-[(1s,2e,4e)-5-carboxy-1-[(3-carboxypropanoyl)oxy]-4-methylpenta-2,4-dien-1-yl]-2-hexyl-8-methyl-1,6-dioxaspiro[4.5]decan-7-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

C38H56O11 (688.3822)


   

methyl (1s,2r,5s,12s,15e,24r,25r,26r,28s,40s)-15-ethylidene-34-methoxy-24,30,39-trimethyl-4,6-dioxa-10,17,30,39-tetraazaundecacyclo[26.10.1.1¹⁴,²⁰.0²,²⁶.0⁵,²⁵.0⁷,²³.0⁹,²¹.0¹¹,²⁰.0¹²,¹⁷.0²⁹,³⁷.0³¹,³⁶]tetraconta-7(23),8,10,21,29(37),31,33,35-octaene-40-carboxylate

methyl (1s,2r,5s,12s,15e,24r,25r,26r,28s,40s)-15-ethylidene-34-methoxy-24,30,39-trimethyl-4,6-dioxa-10,17,30,39-tetraazaundecacyclo[26.10.1.1¹⁴,²⁰.0²,²⁶.0⁵,²⁵.0⁷,²³.0⁹,²¹.0¹¹,²⁰.0¹²,¹⁷.0²⁹,³⁷.0³¹,³⁶]tetraconta-7(23),8,10,21,29(37),31,33,35-octaene-40-carboxylate

C42H48N4O5 (688.3625)


   

4-({2-hydroxy-2-[3-hydroxy-4-(10-hydroxy-3,7,9,11,13,15-hexamethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl)pentan-2-yl]-6-isopropyl-5-methyloxan-4-yl}oxy)-4-oxobut-2-enoic acid

4-({2-hydroxy-2-[3-hydroxy-4-(10-hydroxy-3,7,9,11,13,15-hexamethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl)pentan-2-yl]-6-isopropyl-5-methyloxan-4-yl}oxy)-4-oxobut-2-enoic acid

C39H60O10 (688.4186)


   

(2s,3r,4s,5r)-2-[2-(6-chlorododecyl)-5-(6-chloropentadecyl)-3-hydroxyphenoxy]oxane-3,4,5-triol

(2s,3r,4s,5r)-2-[2-(6-chlorododecyl)-5-(6-chloropentadecyl)-3-hydroxyphenoxy]oxane-3,4,5-triol

C38H66Cl2O6 (688.4236)


   

10-[8-(4-carboxy-3-methylbuta-1,3-dien-1-yl)-9-[(4-methoxy-4-oxobutanoyl)oxy]-3-methyl-9-pentyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

10-[8-(4-carboxy-3-methylbuta-1,3-dien-1-yl)-9-[(4-methoxy-4-oxobutanoyl)oxy]-3-methyl-9-pentyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

C38H56O11 (688.3822)


   

methyl (1r,10r,44r,45r)-25-methoxy-4,13-dioxa-17,27,30,40-tetraazatridecacyclo[28.13.1.1¹⁰,¹⁷.0¹,⁵.0⁶,²⁹.0⁸,²⁸.0¹⁰,¹⁴.0²⁰,²⁸.0²¹,²⁶.0³³,⁴¹.0³³,⁴⁴.0³⁴,³⁹.0²⁰,⁴⁵]pentatetraconta-21,23,25,34,36,38,41-heptaene-42-carboxylate

methyl (1r,10r,44r,45r)-25-methoxy-4,13-dioxa-17,27,30,40-tetraazatridecacyclo[28.13.1.1¹⁰,¹⁷.0¹,⁵.0⁶,²⁹.0⁸,²⁸.0¹⁰,¹⁴.0²⁰,²⁸.0²¹,²⁶.0³³,⁴¹.0³³,⁴⁴.0³⁴,³⁹.0²⁰,⁴⁵]pentatetraconta-21,23,25,34,36,38,41-heptaene-42-carboxylate

C42H48N4O5 (688.3625)


   

1,3-bis[(4r,4as,6r,7s,7as)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl] (1r,2r,3r,4s)-2-(4-hydroxy-3-methoxyphenyl)-4-(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

1,3-bis[(4r,4as,6r,7s,7as)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl] (1r,2r,3r,4s)-2-(4-hydroxy-3-methoxyphenyl)-4-(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

C41H56N2O7 (688.4087)


   

4',5'-bis(acetyloxy)-3',4-dihydroxy-7-methoxy-2,3',5a,6,6',9',9b-heptamethyl-8,10'-dioxo-2,3a,4,5,9,9a-hexahydro-1h-11'-oxaspiro[cyclopenta[a]naphthalene-3,2'-tricyclo[7.2.1.0¹,⁶]dodecan]-7'-yl acetate

4',5'-bis(acetyloxy)-3',4-dihydroxy-7-methoxy-2,3',5a,6,6',9',9b-heptamethyl-8,10'-dioxo-2,3a,4,5,9,9a-hexahydro-1h-11'-oxaspiro[cyclopenta[a]naphthalene-3,2'-tricyclo[7.2.1.0¹,⁶]dodecan]-7'-yl acetate

C37H52O12 (688.3459)


   

2-{[1-(2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl)-7,8-dihydroxy-3a,6,6,9b,11a-pentamethyl-10-oxo-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-2-yl]oxy}-6-methyl-5-oxooxan-3-yl acetate

2-{[1-(2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl)-7,8-dihydroxy-3a,6,6,9b,11a-pentamethyl-10-oxo-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-2-yl]oxy}-6-methyl-5-oxooxan-3-yl acetate

C38H56O11 (688.3822)


   

(3r,4r,5r,6s)-6-{[(1s,4r,5s,6r,8r,10s,12s,13s,15s,16r,18s,21r)-15-(acetyloxy)-8-ethoxy-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-18-yl]oxy}-4,5-dihydroxyoxan-3-yl (2e)-but-2-enoate

(3r,4r,5r,6s)-6-{[(1s,4r,5s,6r,8r,10s,12s,13s,15s,16r,18s,21r)-15-(acetyloxy)-8-ethoxy-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-18-yl]oxy}-4,5-dihydroxyoxan-3-yl (2e)-but-2-enoate

C39H60O10 (688.4186)


   

(1'r,2s,3s,3'r,3ar,4r,4'r,5'r,5as,6'r,7's,9'r,9as,9bs)-4',5'-bis(acetyloxy)-3',4-dihydroxy-7-methoxy-2,3',5a,6,6',9',9b-heptamethyl-8,10'-dioxo-2,3a,4,5,9,9a-hexahydro-1h-11'-oxaspiro[cyclopenta[a]naphthalene-3,2'-tricyclo[7.2.1.0¹,⁶]dodecan]-7'-yl acetate

(1'r,2s,3s,3'r,3ar,4r,4'r,5'r,5as,6'r,7's,9'r,9as,9bs)-4',5'-bis(acetyloxy)-3',4-dihydroxy-7-methoxy-2,3',5a,6,6',9',9b-heptamethyl-8,10'-dioxo-2,3a,4,5,9,9a-hexahydro-1h-11'-oxaspiro[cyclopenta[a]naphthalene-3,2'-tricyclo[7.2.1.0¹,⁶]dodecan]-7'-yl acetate

C37H52O12 (688.3459)


   

(2e)-4-{[(2r,4r,5s,6r)-2-hydroxy-2-[(2s,3r,4s)-3-hydroxy-4-[(2s,3s,4e,6e,9s,10s,11r,12e)-10-hydroxy-3,7,9,11,13,15-hexamethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl]-6-isopropyl-5-methyloxan-4-yl]oxy}-4-oxobut-2-enoic acid

(2e)-4-{[(2r,4r,5s,6r)-2-hydroxy-2-[(2s,3r,4s)-3-hydroxy-4-[(2s,3s,4e,6e,9s,10s,11r,12e)-10-hydroxy-3,7,9,11,13,15-hexamethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl]-6-isopropyl-5-methyloxan-4-yl]oxy}-4-oxobut-2-enoic acid

C39H60O10 (688.4186)


   

15-benzyl-8,11,17-trihydroxy-6-(hydroxymethyl)-3-isopropyl-13-methyl-9,12,18-tris(2-methylpropyl)-1,4-dioxa-7,10,13,16-tetraazacyclooctadeca-7,10,16-triene-2,5,14-trione

15-benzyl-8,11,17-trihydroxy-6-(hydroxymethyl)-3-isopropyl-13-methyl-9,12,18-tris(2-methylpropyl)-1,4-dioxa-7,10,13,16-tetraazacyclooctadeca-7,10,16-triene-2,5,14-trione

C36H56N4O9 (688.4047)


   

(3s,6s,9s,12s,15s,18s)-15-benzyl-8,11,17-trihydroxy-6-(hydroxymethyl)-3-isopropyl-13-methyl-9,12,18-tris(2-methylpropyl)-1,4-dioxa-7,10,13,16-tetraazacyclooctadeca-7,10,16-triene-2,5,14-trione

(3s,6s,9s,12s,15s,18s)-15-benzyl-8,11,17-trihydroxy-6-(hydroxymethyl)-3-isopropyl-13-methyl-9,12,18-tris(2-methylpropyl)-1,4-dioxa-7,10,13,16-tetraazacyclooctadeca-7,10,16-triene-2,5,14-trione

C36H56N4O9 (688.4047)


   

(3r,4r,6s,6ar,7s,8ar,10r,12s,12ar,12br)-3-(1-{[(2r,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}ethyl)-4,6,7,10,12-pentamethyl-dodecahydro-3h-naphtho[1,2-c]oxocine-1,8-dione

(3r,4r,6s,6ar,7s,8ar,10r,12s,12ar,12br)-3-(1-{[(2r,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}ethyl)-4,6,7,10,12-pentamethyl-dodecahydro-3h-naphtho[1,2-c]oxocine-1,8-dione

C34H56O14 (688.367)


   

1-{5,6,8a-trimethyl-5-[2-(2-oxo-5h-furan-3-yl)ethyl]-3,4,4a,6,7,8-hexahydronaphthalen-1-yl}methyl 3-{5-[2-(furan-3-yl)ethyl]-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl}methyl propanedioate

1-{5,6,8a-trimethyl-5-[2-(2-oxo-5h-furan-3-yl)ethyl]-3,4,4a,6,7,8-hexahydronaphthalen-1-yl}methyl 3-{5-[2-(furan-3-yl)ethyl]-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl}methyl propanedioate

C43H60O7 (688.4339)


   

10-[8-(4-carboxy-3-methylbuta-1,3-dien-1-yl)-9-[(3-carboxypropanoyl)oxy]-9-hexyl-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

10-[8-(4-carboxy-3-methylbuta-1,3-dien-1-yl)-9-[(3-carboxypropanoyl)oxy]-9-hexyl-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

C38H56O11 (688.3822)


   

(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r)-2-[(1r,2r,3ar,5ar,9as,11ar)-2-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r)-2-[(1r,2r,3ar,5ar,9as,11ar)-2-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

C39H60O10 (688.4186)


   

6-{5'-[7-(1-hydroxy-2,3-dimethoxy-2-methylbutyl)-3,9-dimethoxy-2,4,10-trimethyl-1,6-dioxaspiro[4.5]decan-2-yl]-[2,2'-bioxolan]-5-yl}-2,3,5-trimethyloxane-2,4-diol

6-{5'-[7-(1-hydroxy-2,3-dimethoxy-2-methylbutyl)-3,9-dimethoxy-2,4,10-trimethyl-1,6-dioxaspiro[4.5]decan-2-yl]-[2,2'-bioxolan]-5-yl}-2,3,5-trimethyloxane-2,4-diol

C36H64O12 (688.4398)


   

(2e,4s,5s,6e,8e)-10-[(2r,3s,6s,8s,9r)-8-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-[(3-carboxypropanoyl)oxy]-9-hexyl-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

(2e,4s,5s,6e,8e)-10-[(2r,3s,6s,8s,9r)-8-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-[(3-carboxypropanoyl)oxy]-9-hexyl-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

C38H56O11 (688.3822)


   

(2s,5s,8s,11r)-12,15-dihydroxy-2,5,8-triisopropyl-11-[(4-methoxyphenyl)methyl]-4,10,18-trimethyl-17-propyl-1,7-dioxa-4,10,13,16-tetraazacyclononadeca-12,15-diene-3,6,9,19-tetrone

(2s,5s,8s,11r)-12,15-dihydroxy-2,5,8-triisopropyl-11-[(4-methoxyphenyl)methyl]-4,10,18-trimethyl-17-propyl-1,7-dioxa-4,10,13,16-tetraazacyclononadeca-12,15-diene-3,6,9,19-tetrone

C36H56N4O9 (688.4047)


   

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 2-[2-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 2-[2-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

C39H60O10 (688.4186)


   

methyl 2-(3-ethyl-7-{2-[(3e)-3-ethylidene-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-2-yl]-3-methoxy-3-oxopropyl}-1h,2h,3h,4h-indolo[2,3-a]quinolizin-2-yl)-3-hydroxypropanoate

methyl 2-(3-ethyl-7-{2-[(3e)-3-ethylidene-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-2-yl]-3-methoxy-3-oxopropyl}-1h,2h,3h,4h-indolo[2,3-a]quinolizin-2-yl)-3-hydroxypropanoate

C42H48N4O5 (688.3625)


   

1-[(4ar,5s,6r,8ar)-5,6,8a-trimethyl-5-[2-(2-oxo-5h-furan-3-yl)ethyl]-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl 3-[(4ar,5s,6r,8ar)-5-[2-(furan-3-yl)ethyl]-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl propanedioate

1-[(4ar,5s,6r,8ar)-5,6,8a-trimethyl-5-[2-(2-oxo-5h-furan-3-yl)ethyl]-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl 3-[(4ar,5s,6r,8ar)-5-[2-(furan-3-yl)ethyl]-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl propanedioate

C43H60O7 (688.4339)


   

(2s,3r,4s,5s,6s)-6-[(2r,2's,5r,5'r)-5'-[(2r,3r,4r,5s,7s,9s,10s)-7-[(1r,3s)-1-hydroxy-2,3-dimethoxy-2-methylbutyl]-3,9-dimethoxy-2,4,10-trimethyl-1,6-dioxaspiro[4.5]decan-2-yl]-[2,2'-bioxolan]-5-yl]-2,3,5-trimethyloxane-2,4-diol

(2s,3r,4s,5s,6s)-6-[(2r,2's,5r,5'r)-5'-[(2r,3r,4r,5s,7s,9s,10s)-7-[(1r,3s)-1-hydroxy-2,3-dimethoxy-2-methylbutyl]-3,9-dimethoxy-2,4,10-trimethyl-1,6-dioxaspiro[4.5]decan-2-yl]-[2,2'-bioxolan]-5-yl]-2,3,5-trimethyloxane-2,4-diol

C36H64O12 (688.4398)


   

6-{[15-(acetyloxy)-8-ethoxy-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-18-yl]oxy}-4,5-dihydroxyoxan-3-yl but-2-enoate

6-{[15-(acetyloxy)-8-ethoxy-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-18-yl]oxy}-4,5-dihydroxyoxan-3-yl but-2-enoate

C39H60O10 (688.4186)


   

12,15-dihydroxy-2,5,8-triisopropyl-11-[(4-methoxyphenyl)methyl]-4,10,18-trimethyl-17-propyl-1,7-dioxa-4,10,13,16-tetraazacyclononadeca-12,15-diene-3,6,9,19-tetrone

12,15-dihydroxy-2,5,8-triisopropyl-11-[(4-methoxyphenyl)methyl]-4,10,18-trimethyl-17-propyl-1,7-dioxa-4,10,13,16-tetraazacyclononadeca-12,15-diene-3,6,9,19-tetrone

C36H56N4O9 (688.4047)


   

1,3-bis[(4r,4as,6r,7s,7ar)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl] (1r,3r)-2-(4-hydroxy-3-methoxyphenyl)-4-(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

1,3-bis[(4r,4as,6r,7s,7ar)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl] (1r,3r)-2-(4-hydroxy-3-methoxyphenyl)-4-(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

C41H56N2O7 (688.4087)


   

1,3-bis[(4r,4as,6r,7s,7ar)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl] (1s,2s,3s,4r)-2-(4-hydroxy-3-methoxyphenyl)-4-(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

1,3-bis[(4r,4as,6r,7s,7ar)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl] (1s,2s,3s,4r)-2-(4-hydroxy-3-methoxyphenyl)-4-(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

C41H56N2O7 (688.4087)


   

(3s,6r,7s,10s,13s,16s,21as)-16-[(2s)-butan-2-yl]-8-hydroxy-3,10,13-triisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

(3s,6r,7s,10s,13s,16s,21as)-16-[(2s)-butan-2-yl]-8-hydroxy-3,10,13-triisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

C37H60N4O8 (688.4411)


   

8-hydroxy-3,10,13-triisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-16-(sec-butyl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

8-hydroxy-3,10,13-triisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-16-(sec-butyl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

C37H60N4O8 (688.4411)


   

methyl 4,5-dimethoxy-6-[(1,2,4,5,6-pentamethoxyhexan-3-yl)oxy]-3-{[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy}oxane-2-carboxylate

methyl 4,5-dimethoxy-6-[(1,2,4,5,6-pentamethoxyhexan-3-yl)oxy]-3-{[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy}oxane-2-carboxylate

C30H56O17 (688.3517)


   

methyl (2s,3s,4s,5r,6s)-4,5-dimethoxy-6-{[(2r,3r,4s,5s)-1,2,4,5,6-pentamethoxyhexan-3-yl]oxy}-3-{[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy}oxane-2-carboxylate

methyl (2s,3s,4s,5r,6s)-4,5-dimethoxy-6-{[(2r,3r,4s,5s)-1,2,4,5,6-pentamethoxyhexan-3-yl]oxy}-3-{[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy}oxane-2-carboxylate

C30H56O17 (688.3517)


   

10-(2-{5-carboxy-1-[(3-carboxypropanoyl)oxy]-4-methylpenta-2,4-dien-1-yl}-2-hexyl-8-methyl-1,6-dioxaspiro[4.5]decan-7-yl)-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

10-(2-{5-carboxy-1-[(3-carboxypropanoyl)oxy]-4-methylpenta-2,4-dien-1-yl}-2-hexyl-8-methyl-1,6-dioxaspiro[4.5]decan-7-yl)-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

C38H56O11 (688.3822)


   

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r)-2-[(1r,2r,3ar,5ar,9as,11ar)-2-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r)-2-[(1r,2r,3ar,5ar,9as,11ar)-2-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

C39H60O10 (688.4186)